IP Assignment Strategies and New State Protections: Key Provisions, Mitigating IP Risks, Implications for Litigation

Ms. Li focuses her practice on patent, trademark, and trade secret litigation, counseling, patent procurement, freedom-to-operate, and due diligence. She litigates in both federal and state court, has been lead counsel in IPR proceedings, and has also successfully represented clients at the International Trade Commission (ITC). Her practice covers an array of technologies, with a special emphasis on biotechnology, Hatch-Waxman, medical device, and hand-held electronics industries. Her experience includes patent litigation, trade secret misappropriation, trademark enforcement, false advertising, and unfair competition cases.

Mr. Saxe provides management-side labor and employment litigation defense before federal and state courts in class and collective actions, single-plaintiff litigation, and administrative agency proceedings. In addition to litigation defense, Mr. Saxe provides counsel to a variety of workforce sizes, including but not limited to, those with modest in-house counsel presence, in connection with a broad array of employee relations issues, including wage and hour, human resources management, employment mobility, and equal employment opportunity matters. He advises management on complex issues arising in employment actions (including, but not limited to, individual or group terminations from employment), and he prepares and reviews personnel policies, employee handbooks, employment agreements, and other employment-related materials to ensure a compliant and effective employment platform.

Mr. Potts is a thought leader in developing and monetizing intellectual property assets in the biotech field. With well over a decade of experience as an intellectual property attorney both in-house and as outside counsel, Mr. Potts has built and led IP departments at major publicly traded, multinational companies. Currently, he is the CEO of a startup cell therapy development company that is focused on developing adoptive cell therapies for the treatment of solid tumors such as ovarian, breast, pancreatic, and kidney cancers.